Search results
13 lip 2015 · Pathophysiology and managment of neonatal hyperbilirubinemia. This is a pilot video series. Meant for pediatrics residents as a quick review, with emphasis on why disease presents the way it...
In this video, the viewer will learn the epidemiology, pathophysiology, clinical presentation and management of neonatal jaundice.Direct links to chapters:0:...
Calculator and clinical decision support for the AAP 2022 guidelines for the management of hyperbilirubinemia in newborns 35 or more weeks of gestation. Features. Neurotoxicity risk factors absent, present, or both. Plot multiple time points to assess trends.
5 sie 2022 · This article updates and replaces the 2004 American Academy of Pediatrics (AAP) clinical practice guideline for the management and prevention of hyperbilirubinemia in the newborn infant ≥35 weeks’ gestation. 3 This clinical practice guideline, like the previous one, addresses issues of prevention, risk assessment, monitoring, and treatment.
This AAP clinical guidance assists pediatricians with the diagnosis and management of hyperbilirubinemia in newborns. Tools are provided to ensure early identification of newborns of 35 or more weeks’ gestation at risk for hyperbilirubinemia who might require treatment to prevent kernicterus.
Highlights the challenge of identifying G6PD deficiency in infants. Bases follow-up testing on the difference between bilirubin level and the phototherapy threshold. No more risk zones! Raises thresholds for phototherapy and exchange transfusion.
6 lis 2019 · Neonatal jaundice is a clinical manifestation of elevated total serum bilirubin (TSB), termed neonatal hyperbilirubinemia, which results from bilirubin that is deposited into an infant's skin. The characteristic features of neonatal jaundice include yellowish skin, sclerae, and mucous membranes.
